An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer

Treatment with the anti‐angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for treatment. Here, we present an omics approach where DNA methylation profiles are integrated...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal‐Pandit, Anne‐Lise Børresen‐Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N. Kristensen
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2024-08-01
Σειρά:	Molecular Oncology
Θέματα:	bevacizumab breast cancer chemotherapy DNA methylation epigenetics multiomics
Διαθέσιμο Online:	https://doi.org/10.1002/1878-0261.13656
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!